OneMedNet Corp
For the period ended Dec 31, 2023. Filed Apr 9, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 9, 2024
ONMD$5.82-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year Ended | ||
|---|---|---|
| December 31, 2023 | December 31, 2022 | |
| Cash flow from Operating Activities | ||
| Net Loss | $(23,205,456) | $(6,229,639) |
| Adjustments to reconcile net loss to net cash flows from operating activities: | ||
| Depreciation and amortization | 27,983 | 24,807 |
| Business combination cost | 900,152 | - |
| Stock-based compensation expense | - | 1,599,586 |
| Cash Held in Trust Account | 29,029,416 | 88,291,558 |
| Prepaid Expenses | (64,594) | |
| Other current assets | - | (875,803) |
| Accounts payable and accrued Expenses | 1,369,825 | 1,929,787 |
| Accounts receivable, net of allowance | (132,665) | 72,767 |
| Deferred Revenue & Customer Deposits | 70,314 | (458,667) |
| Amount due to related party | (300) | 11,500 |
| Exercise tax liability | 113,353 | |
| Extension loan | 445,840 | 2,545,838 |
| Franchise tax payable | (69,966) | (94,043) |
| Income Tax Payable | (94,833) | 214,850 |
| Working capital loan | (168,159) | 207,081 |
| Net cash flows used in operating activities | $8,220,910 | $87,239,622 |
| Cash used for Investing Activities | ||
| Purchase of property and equipment | $(43,757) | $(58,137) |
| Cash flow from Financing Activities | ||
| Class B Common Stock | - | 137 |
| Proceeds (repayment) from issuance of convertible promissory note payable | (10,680,772) | 5,543,162 |
| Proceeds from issuance of PIPE Convertible Notes and Warrants | 1,549,820 | |
| Proceed from related party loan | 465,024 | - |
| Proceeds from Canada Emergency Business Loan Act | 529 | (2,754) |
| Common Stock Subject to Redemption | (28,750,109) | (88,549,890) |
| Deferred underwriting fee | (500,000) | - |
| Warrant liability | (337,976) | (4,489,110) |
| Additional Paid-in Capital | 18,189,350 | 2,825,823 |
| Class A Common Stock | (59) | - |
| Class B Common Stock | (425) | - |
| Retained Earnings adjustment | 11,632,743 | (3,359,594) |
| Net cash flows from financing activities | (8,431,875) | (88,032,226) |
| Net change in cash and cash equivalents | (254,722) | (850,741) |
| Cash and Cash Equivalents, Beginning | 301,730 | 1,152,471 |
| Cash and Cash Equivalents, Ending | 47,008 | 301,730 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.